As business leaders, we are called on now more than ever to make sure our workplaces are truly welcoming to talented people, irrespective of their background or gender identity.
Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end and commercialization on the other.
The CEO Of Aristea talks about the company’s unusual move to do both a Series B round, but not as a crossover, while also making a deal with another pharma company.
This article is the final installment of a three-part series examining how advanced therapy scientific and quality expectations are impacting outsourcing business practices/models today and, hopefully, creating a foundation for greater risk-sharing in the future.
Whether bringing a novel therapy to market or altering current devices for life cycle management, companies must determine the best selection for administration without affecting drug efficacy, quality, and safety.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more
